NEW YORK, Feb. 28, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on ILMN, IMDZ, IMUC, and IMGN which can be accessed for free by signing up to www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com monitors Illumina Inc. (NASDAQ: ILMN), Immune Design
On Tuesday, shares in San Diego, California headquartered Illumina Inc. saw a decline of 1.59%, ending the day at $229.73. The stock recorded a trading volume of 671,130 shares. The Company's shares have advanced 6.92% over the previous three months and 37.71% over the past year. The stock is trading above its 50-day and 200-day moving averages by 0.71% and 13.22%, respectively. Moreover, shares of Illumina, which provides sequencing and array-based solutions for genetic analysis, have a Relative Strength Index (RSI) of 53.32.
On January 30th, 2018, Illumina announced its financial results for the Q4 FY17 and FY17. For Q4 2017, revenue was $778 million, GAAP net income attributable to Company stockholders was $68 million, and cash flow from operations was $294 million. For the full year 2017, revenue was $2,752 million, GAAP net income attributable to Company stockholders was $726 million, and cash flow from operations was $875 million.
On February 05th, 2018, research firm Citigroup upgraded the Company's stock rating from 'Neutral' to 'Buy'. Get the full research report on ILMN for free by clicking below at:
Shares in Seattle, Washington headquartered Immune Design Corp. ended the day 3.08% lower at $3.15 with a total trading volume of 285,966 shares. The stock is trading below its 50-day moving average by 12.50%. Shares of the Company, which engages in the research and development for vivo immunotherapy treatments, have an RSI of 40.16.
On February 09th, 2018, Immune Design announced that senior management will present at the Cowen & Company 38th Annual Health Care Conference on March 12th, 2018, at 12:00 p.m. ET in Boston. A live webcast of the presentation will be available under the investor relations page of the Company's corporate website. Today's complimentary research report on IMDZ is accessible at:
At the close of trading on Tuesday, shares in Calabasas, California-based ImmunoCellular Therapeutics Ltd finished 1.58% lower at $0.27 with a total trading volume of 868,628 shares. The stock is trading below its 50-day moving average by 5.80%. Shares of the Company, which develops immune-based therapies for the treatment of various cancers, have an RSI of 51.91.
On February 13th, 2018, ImmunoCellular Therapeutics announced that during Q4 ended December 31st, 2017, the Company received approximately $5.77 million of gross proceeds from the exercise of warrants in connection with the July 2017 underwritten public offering. The Company ended 2017 with approximately $6.6 million in cash. Register now for your free research document on IMUC at:
Waltham, Massachusetts headquartered ImmunoGen Inc.'s shares recorded a trading volume of 3.00 million shares at the end of yesterday's session. The stock closed the day 0.73% lower at $10.92. The Company's shares have surged 30.47% in the past month, 82.91% in the previous three months, and 232.93% over the past year. The stock is trading above its 50-day and 200-day moving averages by 31.69% and 64.25%, respectively. Additionally, shares of ImmunoGen, which develops targeted anticancer therapeutics, have an RSI of 62.23.
On February 06th, 2018, ImmunoGen announced that its management will present at the Cowen and Company 38th Annual Health Care Conference on March 13th, 2018 at 8:40 a.m. ET. A webcast of the presentation will be available under the Investors section of the Company's website.
On February 08th, 2018, research firm RBC Capital Markets resumed its 'Outperform' rating on the Company's stock, with a target price of $12 per share. Click on the link below and see our free report on IMGN at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/whats-happening-with-these-biotech-stocks----illumina-immune-design-immunocellular-therapeutics-and-immunogen-300605581.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!